JP5496671B2 - 修飾自己組織化ペプチド - Google Patents

修飾自己組織化ペプチド Download PDF

Info

Publication number
JP5496671B2
JP5496671B2 JP2009530404A JP2009530404A JP5496671B2 JP 5496671 B2 JP5496671 B2 JP 5496671B2 JP 2009530404 A JP2009530404 A JP 2009530404A JP 2009530404 A JP2009530404 A JP 2009530404A JP 5496671 B2 JP5496671 B2 JP 5496671B2
Authority
JP
Japan
Prior art keywords
seq
peptide
self
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009530404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010504972A5 (enExample
JP2010504972A (ja
Inventor
章弘 堀井
ジャン、シュグアン
ワン、シュメイ
ゲライン、ファブリツィオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2010504972A publication Critical patent/JP2010504972A/ja
Publication of JP2010504972A5 publication Critical patent/JP2010504972A5/ja
Application granted granted Critical
Publication of JP5496671B2 publication Critical patent/JP5496671B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/38—Materials or treatment for tissue regeneration for reconstruction of the spine, vertebrae or intervertebral discs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
JP2009530404A 2006-09-26 2007-09-26 修飾自己組織化ペプチド Expired - Fee Related JP5496671B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84730306P 2006-09-26 2006-09-26
US60/847,303 2006-09-26
PCT/US2007/020754 WO2008039483A2 (en) 2006-09-26 2007-09-26 Modified self-assembling peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013229859A Division JP2014062102A (ja) 2006-09-26 2013-11-05 修飾自己組織化ペプチド

Publications (3)

Publication Number Publication Date
JP2010504972A JP2010504972A (ja) 2010-02-18
JP2010504972A5 JP2010504972A5 (enExample) 2010-11-11
JP5496671B2 true JP5496671B2 (ja) 2014-05-21

Family

ID=39230811

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2009530404A Expired - Fee Related JP5496671B2 (ja) 2006-09-26 2007-09-26 修飾自己組織化ペプチド
JP2013229859A Pending JP2014062102A (ja) 2006-09-26 2013-11-05 修飾自己組織化ペプチド
JP2015158226A Expired - Fee Related JP6224040B2 (ja) 2006-09-26 2015-08-10 修飾自己組織化ペプチド
JP2017129570A Expired - Fee Related JP6430595B2 (ja) 2006-09-26 2017-06-30 修飾自己組織化ペプチド

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013229859A Pending JP2014062102A (ja) 2006-09-26 2013-11-05 修飾自己組織化ペプチド
JP2015158226A Expired - Fee Related JP6224040B2 (ja) 2006-09-26 2015-08-10 修飾自己組織化ペプチド
JP2017129570A Expired - Fee Related JP6430595B2 (ja) 2006-09-26 2017-06-30 修飾自己組織化ペプチド

Country Status (5)

Country Link
US (1) US8022178B2 (enExample)
EP (2) EP2860194B1 (enExample)
JP (4) JP5496671B2 (enExample)
ES (1) ES2709125T3 (enExample)
WO (1) WO2008039483A2 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9327010B2 (en) 2005-04-25 2016-05-03 Massachusetts Institute Of Technology Compositions and methods for promoting hemostasis and other physiological activities
CN101472620A (zh) 2006-04-25 2009-07-01 麻省理工学院 用于影响污染物、机体流体或其它实体移动和/或影响其它生理状况的组合物和方法
US20090112215A1 (en) 2007-10-29 2009-04-30 Sherman Jason T Opto-electric indicators for orthopaedic instruments
EP2345433B1 (en) * 2008-10-06 2017-03-01 3-D Matrix, Ltd. Tissue plug
CN102348717B (zh) † 2009-03-09 2015-11-25 株式会社美你康 自组装肽和高强度肽凝胶
JP2011012042A (ja) * 2009-07-03 2011-01-20 Three D Matrix:Kk 核酸徐放担体
US20110117195A1 (en) * 2009-11-18 2011-05-19 National Cheng Kung University Method for improving myocardial infarction by intramyocardial or transendocardial injection of peptide nanofibers
US9439941B2 (en) 2009-12-14 2016-09-13 The University Of Hong Kong Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells
WO2011132018A1 (en) 2010-04-19 2011-10-27 Universita' Degli Studi Di Milano Bicocca Novel self-assembling peptides and their use in the formation of hydrogels
US8741833B2 (en) 2010-07-16 2014-06-03 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
WO2012008967A1 (en) * 2010-07-16 2012-01-19 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
WO2012027218A2 (en) 2010-08-27 2012-03-01 Corning Incorporated Peptide-modified surfaces for cell culture
US20130281602A1 (en) * 2010-10-08 2013-10-24 Solvay Sa Thermo-responsive polymer covalently bound with a peptide
JP2012082180A (ja) * 2010-10-14 2012-04-26 Nagoya Univ 骨再生用自己組織化ペプチドハイドロゲル
JP6084352B2 (ja) * 2010-12-24 2017-02-22 国立大学法人 岡山大学 高強度ペプチドゲル
WO2012162637A2 (en) 2011-05-26 2012-11-29 Kansas State University Research Foundation Vaccine adjuvants from self-assembling peptides
GB2496654A (en) 2011-11-18 2013-05-22 Reckitt & Colman Overseas Self-assembling peptides
EP2607373A1 (en) * 2011-12-23 2013-06-26 Solvay Sa Liquid phase synthesis of self-assembling peptides to be linked to polymers or to other bioactive and/or self-assembling peptides
CN103288929A (zh) * 2012-03-01 2013-09-11 上海中医药大学 一种促进移植干细胞存活和分化的纳米生物材料
KR101348096B1 (ko) 2012-03-29 2014-01-09 한국과학기술연구원 줄기세포의 연골 분화 유도 활성을 가지는 폴리펩타이드
CN102952176A (zh) * 2012-05-22 2013-03-06 西北工业大学 具有促成骨生长的生物活性多肽及其制备方法
JP6389170B2 (ja) 2012-07-06 2018-09-12 スリーディー マトリックス， エルティーディー３−Ｄ Ｍａｔｒｉｘ， Ｌｔｄ． ペプチド溶液のためのフィル−フィニッシュ過程
ES2933048T3 (es) * 2012-08-17 2023-01-31 Amsilk Gmbh Uso de polipéptidos de autoensamblaje como adhesivos tisulares
WO2014056199A1 (zh) * 2012-10-12 2014-04-17 清华大学 多肽的产生和纯化方法
US9642695B2 (en) 2012-10-26 2017-05-09 Jms Co., Ltd. Artificial blood vessel, and method for producing artificial blood vessel
US9241891B2 (en) 2012-10-30 2016-01-26 The Procter & Gamble Company Personal care compositions comprising self-assembling peptides
CA2886109A1 (en) * 2012-12-07 2014-06-12 Kansas State University Research Foundation Peptide-albumin hydrogel properties and its applications
KR20160003651A (ko) * 2013-03-14 2016-01-11 가부시끼가이샤 쓰리디 매트릭스 위장 폐색 예방용 물질
EP2968135A4 (en) * 2013-03-14 2016-10-26 Massachusetts Inst Technology INJECTABLE, MULTILAYER, SELF-COMPOSITE PEPTIDE RUBBER HYDROGELS FOR LONG-TERM AND DELAYED RELEASE OF HUMAN ANTIBODIES
US9526762B1 (en) 2013-08-09 2016-12-27 William Marsh Rice University Multidomain peptides for promoting angiogenesis
WO2015022883A1 (ja) 2013-08-14 2015-02-19 独立行政法人理化学研究所 光透過性に優れた生物材料を調製するための組成物およびその利用
CN105658252A (zh) * 2013-08-22 2016-06-08 阿奇生物外科有限公司 用于控制流体移动的可植入网状物
ES2712608T3 (es) 2014-03-10 2019-05-14 3 D Matrix Ltd Péptidos autoensamblantes para el tratamiento de las bullas pulmonares
CA2939696C (en) 2014-03-10 2023-01-10 3-D Matrix, Ltd. Self-assembling peptide compositions
JP6684719B2 (ja) 2014-03-10 2020-04-22 株式会社スリー・ディー・マトリックス ペプチド組成物の滅菌および濾過
KR101595063B1 (ko) * 2014-04-24 2016-02-18 단국대학교 천안캠퍼스 산학협력단 세포결합 서열, 헤파린 결합 도메인 및 오스테오칼신 도메인을 포함하는 융합단백질 및 이를 포함하는 약학 조성물
WO2015194194A1 (en) * 2014-06-20 2015-12-23 3-D Matrix, Ltd. Materials and methods for filling bone voids
US10821136B2 (en) 2014-06-30 2020-11-03 National University Corporation Tokai National Higher Education And Research System Bone formation promoter
WO2016004216A2 (en) * 2014-07-01 2016-01-07 Vicus Therapeutics, Llc Hydrogels for treating and ameliorating infections and methods of making and using them
US10201338B1 (en) 2014-09-10 2019-02-12 Abyrx, Inc. Device for the application of surgical materials to tissue
KR101678740B1 (ko) * 2014-10-24 2016-11-23 단국대학교 천안캠퍼스 산학협력단 세포 부착활성 및 골분화 촉진활성을 나타내는 피브로넥틴 융합단백질
PT3219330T (pt) * 2014-11-14 2020-01-17 3 D Matrix Ltd Síntese de nano agregado de quitosano modificado por péptido de auto-montagem e sua aplicação na aplicação de proteína
DE102015000363A1 (de) 2015-01-20 2016-07-21 Emc Microcollections Gmbh Neue modular funktionalisierbare Peptid-Hydrogele
JP6886402B2 (ja) 2015-08-24 2021-06-16 株式会社スリー・ディー・マトリックス 生分解性インジェクタブルゲル
US10800822B2 (en) 2015-11-30 2020-10-13 The Board Of Trustees Of The University Of Illinois Histatins and method of use thereof
WO2017120092A1 (en) 2016-01-06 2017-07-13 3-D Matrix, Ltd. Combination compositions
CN105669870B (zh) * 2016-03-16 2020-01-10 重庆医科大学附属第一医院 自组装多肽d-RADA16-RGD及其制备方法和应用
US11246924B2 (en) 2016-04-01 2022-02-15 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
EP3463495A1 (en) * 2016-06-01 2019-04-10 3-D Matrix Ltd. Hemostatic dressings with self-assembling peptide hydrogels
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
US11185568B2 (en) * 2017-04-14 2021-11-30 President And Fellows Of Harvard College Methods for generation of cell-derived microfilament network
US20220387605A1 (en) * 2017-07-18 2022-12-08 Duke University Compositions and methods comprising self-assembling peptide-polymer nanofibers for sublingual immunization
EP3723726A1 (en) 2017-12-15 2020-10-21 3-D Matrix, Ltd. Surfactant peptide nanostructures and uses in drug delivery
WO2020171161A1 (ja) * 2019-02-20 2020-08-27 国立大学法人東京農工大学 自己組織化ペプチド
CN110256572B (zh) * 2019-05-07 2022-11-01 西北大学 一种rhc-(rada)4融合蛋白
US20220088275A1 (en) * 2019-05-20 2022-03-24 Convalesce Inc. Hydrogels, methods of making, and methods of use
CN110201184A (zh) * 2019-05-28 2019-09-06 南方医科大学珠江医院 双靶向配体的心脑微血管药物及其制备方法
EP3952973B1 (en) 2019-06-13 2023-06-07 Hollister Incorporated Reusable urinary catheter products
AU2020304005B2 (en) 2019-06-25 2025-12-04 Hollister Incorporated Reusable urinary catheter products
WO2021062374A1 (en) 2019-09-27 2021-04-01 Duke University Tabletization of peptide self-assemblies and methods of making and using the same
US20210106506A1 (en) * 2019-10-11 2021-04-15 Elc Management Llc Methods for cosmetic skin remodeling
JP7537678B2 (ja) * 2020-03-16 2024-08-21 国立大学法人 東京医科歯科大学 自己組織化ペプチドを含む組成物
US20230203116A1 (en) * 2020-07-30 2023-06-29 National University Corporation Tokyo Medical And Dental University Self-assembling peptide
JP2024506048A (ja) * 2021-02-10 2024-02-08 株式会社スリー・ディー・マトリックス 特異的な自己組織化ペプチドｒａｄａ１６を含む、炎症性腸疾患などの下部消化管疾患を治療又は予防するための医薬組成物
JP2024507871A (ja) * 2021-02-23 2024-02-21 ノースウェスタン ユニバーシティ 動力学的生理活性足場及びｃｎｓ損傷後のその治療的使用
CN113512094B (zh) * 2021-06-29 2023-04-14 兰州大学 一种共价光交联多肽、共价光交联多肽自组装形成的胶原蛋白仿生材料
CN114230640A (zh) * 2021-12-21 2022-03-25 西安交通大学 一种具有自组装能力的氨基酸缩合物
CN116715730A (zh) * 2023-04-27 2023-09-08 暨南大学 一种自组装小分子肽及其在抗血管生成中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315074A (en) * 1978-05-19 1982-02-09 Pierce Chemical Company Molecular transformation procedure
GB8427651D0 (en) * 1984-11-01 1984-12-05 Beecham Group Plc Compounds
US5109113A (en) * 1986-05-02 1992-04-28 Genentech, Inc. Membrane anchor fusion polypeptides
IL85372A (en) 1987-02-12 1992-12-01 Us Health Penta to nona-peptides with laminin - like activity having an amino acid sequence and anti- metastatic compositions containing them
US5843156A (en) 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
ES2054365T3 (es) * 1989-06-30 1994-08-01 Massachusetts Inst Technology Inhibicion de la via de la regla del n final en celulas vivas.
US5670483A (en) 1992-12-28 1997-09-23 Massachusetts Insititute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US5955343A (en) 1992-12-28 1999-09-21 Massachusetts Institute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US5763212A (en) * 1994-02-04 1998-06-09 California Institute Of Technology Inhibiting degradation of a degron-bearing protein
US6673604B1 (en) 1999-07-23 2004-01-06 Diacrin, Inc. Muscle cells and their use in cardiac repair
JP2001161813A (ja) * 1999-12-09 2001-06-19 Nissho Corp 医療用チューブ
JP2003520050A (ja) 2000-01-24 2003-07-02 フィロス インク． タンパク質分析のための高感度多重化診断アッセイ法
US6884778B2 (en) * 2000-04-14 2005-04-26 William Marsh Rice University Biocompatible macromers
ATE419333T1 (de) * 2001-02-06 2009-01-15 Massachusetts Inst Technology Peptidgerüstverkapselung von gewebszellen und verwendungen davon
US7449180B2 (en) 2001-02-06 2008-11-11 John Kisiday Macroscopic scaffold containing amphiphilic peptides encapsulating cells
WO2003096972A2 (en) 2002-05-13 2003-11-27 Massachusetts Institute Of Technology Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof
CA2387257C (en) 2002-05-23 2009-07-28 Suncor Energy Inc. Static deaeration conditioner for processing of bitumen froth
JP4419448B2 (ja) * 2003-06-17 2010-02-24 株式会社ジェイ・エム・エス 医療用チューブ
US7713923B2 (en) 2003-06-25 2010-05-11 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
DK1636250T3 (en) * 2003-06-25 2016-02-22 Massachusetts Inst Technology SELF-ORGANIZING PEPTIDES, CONTAINING MODIFICATIONS, AND APPLICATIONS THEREOF
US7884185B2 (en) * 2004-07-28 2011-02-08 University Of Delaware Hydrogels and uses thereof
US7429567B2 (en) 2005-01-04 2008-09-30 The Brigham And Women's Hospital, Inc. Sustained delivery of PDGF using self-assembling peptide nanofibers
US9327010B2 (en) 2005-04-25 2016-05-03 Massachusetts Institute Of Technology Compositions and methods for promoting hemostasis and other physiological activities

Also Published As

Publication number Publication date
JP6430595B2 (ja) 2018-11-28
EP2066697A2 (en) 2009-06-10
WO2008039483A9 (en) 2009-04-16
ES2709125T3 (es) 2019-04-15
JP2010504972A (ja) 2010-02-18
US20090162437A1 (en) 2009-06-25
JP2014062102A (ja) 2014-04-10
EP2860194B1 (en) 2018-11-07
JP2018019682A (ja) 2018-02-08
WO2008039483A3 (en) 2008-11-27
JP2016028689A (ja) 2016-03-03
JP6224040B2 (ja) 2017-11-01
EP2860194A1 (en) 2015-04-15
WO2008039483A2 (en) 2008-04-03
US8022178B2 (en) 2011-09-20

Similar Documents

Publication Publication Date Title
JP6430595B2 (ja) 修飾自己組織化ペプチド
JP5057781B2 (ja) 修飾を組み込んだ自己集合ペプチドおよびそれを使用する方法
US7713923B2 (en) Self-assembling peptides incorporating modifications and methods of use thereof
Jain et al. Controlling neuronal cell growth through composite laminin supramolecular hydrogels
Huang et al. A functional biphasic biomaterial homing mesenchymal stem cells for in vivo cartilage regeneration
Shao et al. Polycaprolactone electrospun mesh conjugated with an MSC affinity peptide for MSC homing in vivo
Huang et al. 3-D self-assembling leucine zipper hydrogel with tunable properties for tissue engineering
Fernández-Muiños et al. Bimolecular based heparin and self-assembling hydrogel for tissue engineering applications
KR101265492B1 (ko) 줄기세포를 혈관세포로 분화시키는 방법 및 이를 이용한 생체 내 혈관신생 유도
KR20160091993A (ko) 바이오패브리케이션 및 프린팅을 위한 빌딩 블록으로서의 자기 조립형 펩티드, 펩티드 모방체 및 펩티드 접합체
US20140341874A1 (en) Dextran-based tissuelette containing platelet-rich plasma lysate for cartilage repair
Little et al. Exploiting bacterial peptide display technology to engineer biomaterials for neural stem cell culture
Pugliese et al. Functionalization of self-assembling peptides for neural tissue engineering
JP6797389B1 (ja) 細胞外マトリックス含有組成物及びその製造方法、並びに三次元組織体及びその製造方法
CA2530482A1 (en) Self-assembling peptides incorporating modifications and methods of use thereof
Alshehri 3D Scaffolds from Self Assembling Ultrashort Peptide for Tissue Engineering and Disease Modeling
Song A Bioorthogonal Hydrogel Platform for the Development of an Engineered Vocal Fold Tissue Model
Colquhoun Manipulating the Properties of Hydrogels to Promote Ependymal Cell Behaviour for Spinal Cord Repair
JP2022036357A (ja) 細胞構造体及び細胞構造体の製造方法
Zhu The Development of Biomimetic Biomaterials to Present Microenvironmental Cues for the Regulation of hBMSC Differentiations
Li Designing self-assembled multicomponent scaffolds for regenerative medicine
Ferreira Molecularly designed self-assembling matrices for applications in regenerative medicine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130110

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130416

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131105

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140305

R150 Certificate of patent or registration of utility model

Ref document number: 5496671

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees